Advances in the management of pediatric asthma: A review of recent FDA drug approvals and label updates

Journal of Asthma

Volumn 42, Issue 8, 2005, Pages 615-622

  Kemp, James P ^a  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVAIR DISKUS; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORADIL AEROLIZER; FORMOTEROL; FORMOTEROL FUMARATE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; LONG ACTING DRUG; MONTELUKAST; OMALIZUMAB; PEPTIDOLEUKOTRIENE; PHOSPHODIESTERASE INHIBITOR; PULMICORT RESPULE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CLINICAL TRIAL; DRUG APPROVAL; DRUG FORMULATION; DRUG INDICATION; DRUG LABELING; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; GROWTH RETARDATION; HEALTH CARE SYSTEM; HUMAN; INHALER; OUTPATIENT; PREVALENCE; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG LABELING; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 27744600024     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900500214775     Document Type: Review

References (62)

1. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002; 110(5 suppl): S141-S219.
2. National Center for Health Statistics. Fast Stats: Asthma, 2003. http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed October 20, 2003.
3. Hing E, Middleton K. National Hospital Ambulatory Medical Care Survey: 2001 outpatient department summary. Adv Data 2003; 338:1-26.
4. Environmental Protection Agency. Asthma Facts. 2004. EPA 402-F-04-019.
5. McCaig LF, Burt CW. National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary. Adv Data 2004; 340):1-34.
6. National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2000-2001, 2001. http://www.cdc.gov/nchs/products/pubs/pubd/ hestats/asthma/asthma.htm. Accessed April 1, 2003.
7. Uses of drugs not described in the package insert (off-label uses). Pediatrics 2002; 110(1 Pt 1):181-183.
8. One Hundred Seventh Congress of the United States of America. Best Pharmaceuticals for Children Act. Washington, D.C.: Government Printing Office, 2001:S.1789-1-S.1789-17.
9. Roberts R. The federal government: recent changes at FDA and the implications for pediatric clinical trials. 2002:1-45.
10. National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH Publication No. 97-4051, 1997:1-152.
11. American Academy of Allergy Asthma and Immunology. Pediatric asthma: promoting best practice: guide for managing asthma in children. Am Acad Pediatr 1999:1-157.
12. Spahn JD, Szefler SJ. Childhood asthma: new insights into management. J Allergy Clin Immunol 2002; 109(1):3-13.
13. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteioid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106(6):1209-1226.
14. Advair Diskus® Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, 2004:RL-2128.
15. Wildhaber JH. Nebuliser therapy in children. In: Business Briefing: Global Healthcare 2003. 5th ed. London: World Medical Association, Business Briefings Ltd., 2003:91-93.
16. Food and Drug Administration. CDER 2003 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, MD: FDA, 2004.
17. Skoner DP, Szefler SJ, Welch M. Walton-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol 2000; 105(2 Pt 1):259-268.
18. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109(4):730-742.
19. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immun 1999; 83(3):231-239.
20. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998; 102(5):789-796.
21. Baker JW, Mellon M, Wald J. Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103(2):414-421.
22. Scott MB, Ellis MH, Cruz-Rivera M, Fitzpatrick S, Smith JA. Once-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma. Ann Allergy Asthma Immun 2001; 87(6):488-495.
23. Leflein JG, Szefler SJ, Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, Smith JA. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002:866-872.
24. Forest Pharmaceuticals. 1. Aerobid Package Insert. 2002.
25. Food and Drug Administration. Aerobid Black Box Letter (Supplemental NDA). Forest Pharmaceuticals, Inc., 2003. http://www.fda.gov/cdcr/foi/appletter/ 2003/18340s1r0211tr.pdf. Accessed September 22, 2004.
26. Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Expert Opin Pharmacother 2004; 5(5):1163-1173.
27. Food and Drug Administration. FDA Approves Foradil Aerolizer (Formoterol Fumarate Inhalation Powder). Rockville, MD: FDA, 2002:1-4. Report no. 20-831.
28. Foradil® Aerolizer™ (formoterol fumarate inhalation powder). In: Physicians' Desk Reference. 57 ed. Montvale, NJ: Thomson PDR, 2003:2275-2278.
29. Pearlman DS, Kottakis J, Till D, Della CG. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin 2002; 18(8):445-455.
30. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, Castellsague J, Della CG. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immun 2002; 89(2):180-190.
31. 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000; 29(3):221-234.
32. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 2001; 17(3):368-373.
33. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; 117(1):156-162.
34. Food and Drug Administration. FDA Talk Paper: Study of Asthma Drug-Halted. Rockville, MD: FDA, 2003:T03-T06.
35. US Food and Drug Administration. Labeling Changes for Drug Products That Contain Salmeterol. Washington, DC: FDA, 2003:1-2, T03-62.
36. Wooltorton E. Salmeterol (Serevent) asthma trial halted early. CMAJ 2003; 168(6):738.
37. Rickard KA. GlaxoSmithKline. Prescriber of Serevent. Healthcare Professional, 2003.
38. 2-agonists as a combined therapy in asthma. Expert Opin Pharmacother 2003; 4(1):23-39.
39. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003; 111(5):1032-1040.
40. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001; 107(2):381-390.
41. Chowdhury BA. Department of Health and Human Services. NDA 21-409/S-003: Singulair (Montelukast Sodium) Oral Granuals; Application Approval. Hanlon, W. A. and Merck Research Laboratories, 2002.
42. Merck and Co. Inc. Singulair (Montelukast Sodium) Tablets, Chewable Tablets, and Oral Granules. Whitehouse Station, NJ: Merck and Co. Inc., 2002:1-15, 9088815.
43. Dubus JC, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol 2003; 14(1):4-9.
44. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3):1-10.
45. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003; 111(2):301-307.
46. Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Ann Allergy Asthma Immun 2001; 86(6):655-658.
47. US Food and Drug Administration. Summary of Safety-Related Drug Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) April 2001, 2001. http://www.fda.gov/medwatch/safety/2001/apr01.htm. Accessed March 26, 2003.
48. Pearlman DS, Lampl KL, Dowling PJ Jr, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000; 22(6):732-747.
49. McMillan RM. Leukotrienes in respiratory disease. Paediatr Respir Rev 2001; 2(3):238-244.
50. Carl JC, Kercsmar CM. Management of acute pediatric asthma. Curr Allergy Asthma Rep 2002; 2(6):468-476.
51. Strunk RC, Nicklas RA, Milgrom H, Ikle D. Fatal and near-fatal asthma questionnaire: prelude to a national registry. J Allergy Clin Immunol 1999; 104(4Pt 1):763-768.
52. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors. Clin Rev Allergy Immunol 1996; 14(1):37-45.
53. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002; 109(3):449-454.
54. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998; 11(1):1-6.
55. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001; 124(4):478-484.
56. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998; 53(3):347-354.
57. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108(6):938-945.
58. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102(6 Pt 1):943-952.
59. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103(4):615-621.
60. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143(6):731-736.
61. US Department of Health and Human Services. FDA Acts to Make Drugs Safer for Children. Washington, DC: FDA, 2003, Report no. P98-37.
62. Accolate® Zafirlukast tablets. In: Physicians' Desk Reference. 57 ed. Montvale, NJ: Thomson PDR, 2003:651-653.